Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML

Sussman, Robyn T.; Manning, Bryan; Ackerman, Daniel; Bigdeli, Ashkan; Pammer, Paige; Velu, Priya; Luger, Selina M.; Bagg, Adam; Carroll, Martin; Morrissette, Jennifer J.D.

doi:10.1016/j.cancergen.2021.04.004

Search citation statements

Order By: Relevance

Paper Sections

Select...

Myeloid Leukemia Of Down Syndrome (Ml-ds)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the AML02 Trial (JCCSG) patients with ML-DS were treated separately, and a stratification depended on the response after the inductions were implemented [68,69]. In the MRC AML 12, they were allocated for only four courses of chemotherapy and were not eligible for alloHSCT [70]. In the AML-BFM-93 study, the treatment of the DS patients included reduced doses of anthracycline and no high-dose cytarabine/mitoxantrone or cranial irradiation [71].…”

Section: Myeloid Leukemia Of Down Syndrome (Ml-ds)mentioning

confidence: 99%